Yeliva: Phase I final data

Final data from 16 evaluable patients with advanced solid tumors in an open-label, U.S. Phase I trial

Read the full 177 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE